{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:52Z","timestamp":1792783012565,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NHMRC Leadership Fellowship and the Breast Cancer Research Foundation","award":["2026004"],"award-info":[{"award-number":["2026004"]}],"id":[{"id":"https:\/\/ror.org\/0348ff195","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"DOI":"10.1007\/s10689-026-00610-y","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:36:25Z","timestamp":1791444985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of mainstream genetic testing for breast cancer patients: five-year data from the Parkville Familial Cancer Centre"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-0709","authenticated-orcid":false,"given":"Catherine","family":"Beard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7702-4850","authenticated-orcid":false,"given":"Anita","family":"Skandarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-2416","authenticated-orcid":false,"given":"Geoffrey J.","family":"Lindeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Monohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2508-9203","authenticated-orcid":false,"given":"Gregory Bruce","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4361-4657","authenticated-orcid":false,"given":"Paul A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"5","key":"610_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41431-021-00848-3","volume":"29","author":"C Beard","year":"2021","unstructured":"Beard C, Monohan K, Cicciarelli L, James PA (2021) Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre. Eur J Human Genet\u202f: EJHG 29(5):872\u2013880. https:\/\/doi.org\/10.1038\/s41431-021-00848-3","journal-title":"Eur J Human Genet : EJHG"},{"issue":"2","key":"610_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10689-022-00313-0","volume":"22","author":"TP McVeigh","year":"2023","unstructured":"McVeigh TP, Sweeney KJ, Brennan DJ et al (2023) A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and\/or ovarian cancer in three tertiary Cancer Centres in Ireland. Fam Cancer 22(2):135\u2013149. https:\/\/doi.org\/10.1007\/s10689-022-00313-0","journal-title":"Fam Cancer"},{"issue":"10","key":"610_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.5694\/mja2.51317","volume":"215","author":"DL De Silva","year":"2021","unstructured":"De Silva DL, James PA, Mann GB, Lindeman GJ (2021) Universal genetic testing of patients with newly diagnosed breast cancer - ready for prime time? Med J Aust 215(10):449\u2013453. https:\/\/doi.org\/10.5694\/mja2.51317","journal-title":"Med J Aust"},{"issue":"1","key":"610_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygyno.2017.01.030","volume":"145","author":"M Kentwell","year":"2017","unstructured":"Kentwell M, Dow E, Antill Y et al (2017) Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol 145(1):130\u2013136. https:\/\/doi.org\/10.1016\/j.ygyno.2017.01.030","journal-title":"Gynecol Oncol"},{"issue":"1","key":"610_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10689-022-00300-5","volume":"22","author":"ML Ramsey","year":"2023","unstructured":"Ramsey ML, Tomlinson J, Pearlman R et al (2023) Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Fam Cancer 22(1):91\u201397. https:\/\/doi.org\/10.1007\/s10689-022-00300-5","journal-title":"Fam Cancer"},{"issue":"2","key":"610_CR6","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1200\/op.20.00399","volume":"17","author":"T Scheinberg","year":"2021","unstructured":"Scheinberg T, Goodwin A, Ip E et al (2021) Evaluation of a mainstream model of genetic testing for men with prostate cancer. JCO Oncol Pract 17(2):e204\u2013e216. https:\/\/doi.org\/10.1200\/op.20.00399","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"610_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.amjsurg.2016.06.010","volume":"212","author":"KK Ludwig","year":"2016","unstructured":"Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg 212(4):660\u2013669. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.06.010","journal-title":"Am J Surg"},{"issue":"25","key":"610_CR8","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/jco.2012.47.8313","volume":"31","author":"KA Phillips","year":"2013","unstructured":"Phillips KA, Milne RL, Rookus MA et al (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31(25):3091\u20133099. https:\/\/doi.org\/10.1200\/jco.2012.47.8313","journal-title":"J Clin Oncol"},{"issue":"25","key":"610_CR9","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"key":"610_CR10","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2483180\/v1","author":"K Allen","year":"2023","unstructured":"Allen K, Cicciarelli L, Beard C et al (2023) Breast cancer specialists experiences and attitudes towards mainstream genetic testing for patients with breast cancer. Res Square. https:\/\/doi.org\/10.21203\/rs.3.rs-2483180\/v1","journal-title":"Res Square"},{"key":"610_CR11","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4801122\/v1","author":"C Beard","year":"2025","unstructured":"Beard C, Monohan K, Lang N, Cicciarelli L, James PA, Forrest LE (2025) Psychosocial experiences and outcomes for individuals with breast cancer after mainstream genetic testing. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-4801122\/v1","journal-title":"Res Sq"},{"issue":"8","key":"610_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5694\/mja2.51906","volume":"218","author":"DL De Silva","year":"2023","unstructured":"De Silva DL, Stafford L, Skandarajah AR et al (2023) Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care. Med J Aust 218(8):368\u2013373. https:\/\/doi.org\/10.5694\/mja2.51906","journal-title":"Med J Aust"},{"key":"610_CR13","unstructured":"eviQ cancer genetics national reference committee (2025) Risk Management. vol. 19 April. https:\/\/www.eviq.org.au\/cancer-genetics\/adult\/risk-management"},{"issue":"10","key":"610_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/jmedgenet-2017-104584","volume":"54","author":"DG Evans","year":"2017","unstructured":"Evans DG, Harkness EF, Plaskocinska I et al (2017) Pathology update to the Manchester scoring system based on testing in over 4000 families. J Med Genet 54(10):674\u2013681. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104584","journal-title":"J Med Genet"},{"issue":"5","key":"610_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"issue":"3","key":"610_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/humu.24152","volume":"42","author":"C Fortuno","year":"2021","unstructured":"Fortuno C, Lee K, Olivier M et al (2021) Specifications of the ACMG\/AMP variant interpretation guidelines for germline TP53 variants. Hum Mutat 42(3):223\u2013236. https:\/\/doi.org\/10.1002\/humu.24152","journal-title":"Hum Mutat"},{"issue":"9","key":"610_CR17","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","volume":"111","author":"MT Parsons","year":"2024","unstructured":"Parsons MT, de la Hoya M, Richardson ME et al (2024) Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 variant curation expert panel. Am J Hum Genet 111(9):2044\u20132058. https:\/\/doi.org\/10.1016\/j.ajhg.2024.07.013","journal-title":"Am J Hum Genet"},{"issue":"12","key":"610_CR18","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr, Garber JE, Gelber RD et al (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol Off J Eur Soc Med Oncol 33(12):1250\u20131268. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.159","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"5","key":"610_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4428","volume":"2","author":"Z Kemp","year":"2019","unstructured":"Kemp Z, Turnbull A, Yost S et al (2019) Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Netw Open 2(5):e194428. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.4428","journal-title":"JAMA Netw Open"},{"issue":"10","key":"610_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.annonc.2024.07.244","volume":"35","author":"CF Rowlands","year":"2024","unstructured":"Rowlands CF, Allen S, Balma\u00f1a J et al (2024) Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing. Ann Oncol 35(10):892\u2013901. https:\/\/doi.org\/10.1016\/j.annonc.2024.07.244","journal-title":"Ann Oncol"},{"issue":"4","key":"610_CR21","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1245\/s10434-024-16559-0","volume":"32","author":"V Shim","year":"2025","unstructured":"Shim V, Karlea A, Brenman LM et al (2025) ASO visual abstract: impact of mainstream germline genetic testing with expanded eligibility for early stage breast cancer patients in a large integrated health system. Ann Surg Oncol 32(4):2618\u20132619. https:\/\/doi.org\/10.1245\/s10434-024-16559-0","journal-title":"Ann Surg Oncol"},{"key":"610_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.breast.2022.12.001","volume":"67","author":"Q Ain","year":"2023","unstructured":"Ain Q, Richardson C, Mutebi M, George A, Kemp Z, Rusby JE (2023) Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients? Breast 67:30\u201335. https:\/\/doi.org\/10.1016\/j.breast.2022.12.001","journal-title":"Breast"},{"issue":"1","key":"610_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pec.2012.03.019","volume":"89","author":"MR Wevers","year":"2012","unstructured":"Wevers MR, Hahn DE, Verhoef S et al (2012) Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact. Patient Educ Couns 89(1):89\u201395. https:\/\/doi.org\/10.1016\/j.pec.2012.03.019","journal-title":"Patient Educ Couns"},{"key":"610_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep29506","volume":"6","author":"A George","year":"2016","unstructured":"George A, Riddell D, Seal S et al (2016) Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep 6:29506. https:\/\/doi.org\/10.1038\/srep29506","journal-title":"Sci Rep"},{"issue":"2","key":"610_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/ijgc-2019-000630","volume":"30","author":"L McLeavy","year":"2020","unstructured":"McLeavy L, Rahman B, Kristeleit R et al (2020) Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. Int J Gynecol Cancer 30(2):221\u2013226. https:\/\/doi.org\/10.1136\/ijgc-2019-000630","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"610_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajco.13334","volume":"17","author":"T Scheinberg","year":"2021","unstructured":"Scheinberg T, Young A, Woo H, Goodwin A, Mahon KL, Horvath LG (2021) Mainstream consent programs for genetic counseling in cancer patients: a systematic review. Asia Pac J Clin Oncol 17(3):163\u2013177. https:\/\/doi.org\/10.1111\/ajco.13334","journal-title":"Asia Pac J Clin Oncol"},{"key":"610_CR27","unstructured":"Parkville Familial Cancer Centre (2024) Mainstream genetic testing"},{"issue":"5","key":"610_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/jmg-2024-110428","volume":"62","author":"B Torr","year":"2025","unstructured":"Torr B, Kavanaugh G, Hamill M et al (2025) Uptake, utility and resource requirements of a genetic counselling telephone helpline within the BRCA-DIRECT digital pathway for mainstreamed BRCA testing in patients with breast cancer. J Med Genet 62(5):317\u2013325. https:\/\/doi.org\/10.1136\/jmg-2024-110428","journal-title":"J Med Genet"},{"issue":"8","key":"610_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2025.101465","volume":"27","author":"MP Mackley","year":"2025","unstructured":"Mackley MP, Richer J, Guerin A et al (2025) Mainstreaming of clinical genetic testing: a conceptual framework. Genet Med 27(8):101465. https:\/\/doi.org\/10.1016\/j.gim.2025.101465","journal-title":"Genet Med"},{"key":"610_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041059","author":"K Bokkers","year":"2022","unstructured":"Bokkers K, Vlaming M, Engelhardt EG et al (2022) The feasibility of implementing mainstream germline genetic testing in routine cancer care-a systematic review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14041059","journal-title":"Cancers (Basel)"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-026-00610-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:36:28Z","timestamp":1791444988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-026-00610-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1007\/s10689-026-00610-y","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was granted by the Human Research Ethics Committee at both The Royal Melbourne Hospital (QA2018083) and Peter MacCallum Cancer Centre (18\/128L).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"94"}}